Keystone Investors PTE Ltd. Has $21.85 Million Position in Eli Lilly and Company (NYSE:LLY)

Keystone Investors PTE Ltd. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 89.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 26,456 shares of the company's stock after purchasing an additional 12,523 shares during the period. Eli Lilly and Company makes up approximately 3.1% of Keystone Investors PTE Ltd.'s holdings, making the stock its 12th largest position. Keystone Investors PTE Ltd.'s holdings in Eli Lilly and Company were worth $21,850,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Knightsbridge Asset Management LLC lifted its position in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the period. LS Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after purchasing an additional 40 shares during the last quarter. Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $207,000. CSM Advisors LLC grew its stake in shares of Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after purchasing an additional 245 shares during the last quarter. Finally, Hemington Wealth Management increased its stake in shares of Eli Lilly and Company by 14.4% in the 1st quarter. Hemington Wealth Management now owns 985 shares of the company's stock valued at $813,000 after buying an additional 124 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 14.2%

Shares of LLY stock opened at $640.17 on Friday. Eli Lilly and Company has a 52-week low of $633.20 and a 52-week high of $972.53. The company has a market capitalization of $606.71 billion, a PE ratio of 52.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.44. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The business's fifty day moving average is $776.36 and its 200 day moving average is $799.60.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the business earned $3.92 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. Guggenheim lifted their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Finally, HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, five have given a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $999.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.